Expanded Access of Fostamatinib in Patients With Persistent or Chronic Relapsing/Refractory ITP

NCT03363334 · clinicaltrials.gov ↗

NO_LONGER_AVAILABLE

Status

INDUSTRY

Sponsor class

Conditions

Immune Thrombocytopenic Purpura

Interventions

DRUG: Fostamatinib disodium 100 mg
DRUG: Fostamatinib disodium 150 mg

Sponsor

Rigel Pharmaceuticals